Skip to main
SER

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics Inc. is demonstrating a promising outlook due to the advancement of its pipeline candidates, particularly in high-value indications, which suggests potential for significant market opportunities. The company’s valuation assessment currently does not reflect any contribution from SER-270 or other pipeline candidates beyond SER-252, indicating that successful clinical outcomes for SER-270 may lead to substantial upside in future forecasts. Furthermore, the broadening approval footprint of the enFuse product enhances expectations for global acceptance and market penetration of SER-252, reinforcing confidence in the company's growth potential.

Bears say

Serina Therapeutics reported a net loss of $0.64 per share, significantly higher than the previously estimated loss of $0.36 per share, indicating deteriorating financial performance. The company faces multiple risks, including potential delays and failures in advancing its key drug candidate, SER-252, through clinical assessments and regulatory approval processes, which could impact its market viability. Additionally, anticipated commercial uptake may be hindered by increased competition and market dynamics, compounded by possible dilution risks in the near to medium term.

SER has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 2 analysts, SER has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.